Who are Organogenesis's investors?

Organogenesis's investors include Khosla Ventures.

How much funding has Organogenesis raised?

Organogenesis has disclosed $130M raised across 1 round.

Where is Organogenesis headquartered?

Organogenesis is headquartered in Canton, US.

Organogenesis

NASDAQ: ORGO

Canton, US · Founded 1985 · 849 employees on LinkedIn · 1 known investors

Organogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.

Biotech Healthtech Medical Devices

Founders & leadership

Gary S. Gillheeney, Sr.inPresident & CEO

David C. FranciscoChief Financial Officer

Patrick BilboinChief Operating Officer

Brian GrowinChief Commercial Officer

Lori FreedmaninChief Administrative and Legal Officer

Antonio S. MontecalvoinVice President, Health Policy

Robert CavorsiinChief Business Officer

Board

Robert AdesBoard director

Alan A. AdesBoard director

Michele KorfinBoard director

Michael J. DriscollBoard director

Jon GiacominBoard director

Investors · 1

Khosla VenturesMenlo Park · $5K – $50M

Reported raises · per SEC filings

Form D private placements

$130M disclosed across 1 round · 2024

▶$130MraisedNov 2024 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Michele KorfinDirector
Michael J. DriscollDirector
Antonio MontecalvoExecutive Officer
Jon GiacominDirector
Prathyusha DuraibabuDirector
Arthur LeibowitzDirector
Robert AdesDirector
Patrick BilboExecutive Officer
Robert CavorsiExecutive Officer
Gary S. Gillheeney, Sr.Executive Officer, Director
Alan A. AdesDirector
Lori FreedmanExecutive Officer
David C. FranciscoExecutive Officer
David EraniDirector
Glenn H. NussdorfDirector
Garrett LustigDirector
Gilberto QuinteroDirector
Brian GrowExecutive Officer

Offering amount: $130M
Amount sold: $130M
Sales commissions: $5.2M
Proceeds to insiders: $23.5M
Placement agents: Truist Securities, Inc.
First sale: Nov 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Potential 24% Upside For Investorsdirectorstalkinterviews.com · Aug 2026

Organogenesis Q2 2026 earnings: Revenue falls 58% as losses widentradingkey.com · Aug 2026

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers - BioSpacebiospace.com · Jul 2026

Frequently asked questions

What does Organogenesis do?: Organogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.
Who are Organogenesis's investors?: Organogenesis's investors include Khosla Ventures.
How much funding has Organogenesis raised?: Organogenesis has disclosed $130M raised across 1 round.
Where is Organogenesis headquartered?: Organogenesis is headquartered in Canton, US.